Technology Digest Inc., an information technology consulting and product development firm, has made its new home at Johns Hopkins University Montgomery County Campus.
The firm is the brainchild of Sarah Iranpour, a first-generation immigrant to the United States from Iran. Iranpour spent years working for others in the IT field. When her son went to college, she decided to “go after my dream developing something substantial for health and medical.”
In the 21st century, health care innovation is happening at lightning speed. From the mapping of the human genome to the rise of personalized medicines that are linked to advances in molecular medicine, we have seen constant breakthroughs that are changing the face of disease treatment, management, and cures. Health research is moving quickly, but the federal drug and device approval apparatus is in many ways the relic of another era. We have dedicated scientists and bold leaders at agencies like the NIH and the FDA, but when our laws don’t keep pace with innovation, we all lose.
If we want to save more lives and keep this country the leader in medical innovation, we have to make sure there’s not a major gap between the science of cures and the way we regulate these therapies.
Boston-based venture capital firm SV Life Sciences is working on its sixth fund, with a fundraising target of $400 million, according to a Form D filing on the U.S. Securities and Exchange Commission’s website. The firm invests in biotech, medical devices, health IT and healthcare services.
New Enterprise Associates is planing on making a $5 million investment in Speedinvest’s newly launched second fund. NEA is anticipating that it will provide $50 million in follow-on funding for Speedinvest’s portfolio companies. Speedinvest’s second fund will focus on backing European startups.
At Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) we are looking for innovative ways to improve the lives of our nation’s service members, veterans and their families by advancing excellence in psychological health and traumatic brain injury prevention and care. Join our Mental Health and TBI Care Challenge starting May 4 to share your idea on how to fill gaps in care and improve the well-being of people with post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI).
Johns Hopkins University’s Applied Physics Laboratory has been the hidden mastermind behind some of the nation’s most influential technologies for 73 years.
Now the Howard County institution is going deeper into the medical world, while maintaining its foothold in national security and space exploration projects.
Forest City-New East Baltimore Partnership, a joint venture between Forest City Enterprises, Inc. and Presidential Partners LLC, is building a new innovation hub for life sciences in East Baltimore, just north of the Johns Hopkins medical campus. The project is called 1812 Ashland Avenue and is expected to cost $65.6 million.
Ground was broken on Friday, May 15. The new laboratory and office building will have seven levels and about 168,000 square feet of space. It will be the newest addition to the Science + Technology Park at Johns Hopkins and part of the 88-acre East Baltimore Development Inc. renewal area, which is also developed by Forest City-New East Baltimore Partnership.
ProMetic Life Sciences Inc. (PLI)(otcqx:PFSCF) (“ProMetic” or the “Corporation”) announced today that it has entered into an agreement for the acquisition of Emergent BioSolutions’ (“Emergent”) plasma collection center located in Winnipeg, Canada. The transaction is subject to customary closing conditions.
Emergent’s plasma collection center is an FDA and Health Canada licensed plasma collection facility. The plasma collection center is conveniently located in close proximity to the existing Emergent Winnipeg based cGMP manufacturing facility, which was recently announced as providing ProMetic with up to 250,000 liters of annual plasma processing capacity. The plasma collection center will start operating under ProMetic’s ownership upon granting of the regulatory licenses, in ProMetic’s name, by the requisite regulatory authorities. All existing center employees will then transition to be employed by ProMetic.
Partnering with other pharma companies and academic institutions has been a cornerstone strategy for Eli Lilly and Company for close to a hundred years. One of the first major collaborations in the industry occurred in the 1920s when Lilly partnered with Frederick Banting and Charles Best from the University of Toronto. Banting and Best discovered insulin, and Lilly used its resources to develop and commercialize it. Today millions of people continue to benefit from the result of that successful collaboration.
MedImmune and the University of Cambridge today said they have launched a new five-year, multiproject collaboration with the school’s Department of Chemical Engineering and Biotechnology (CEB) focused on research in biopharmaceutical development including cell engineering. The value of the collaboration was not disclosed.
